Loading clinical trials...

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

NCT05338723•Tanta University

View on ClinicalTrials.gov

Summary

This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.

Eligibility

Age

25 - 75 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Age: 25-75 years old.
•Gender: female
•Newly diagnosed HER2 positive breast cancer patients who are scheduled to receive doxorubicin followed by trastuzumab adjuvant therapy.
•Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
•Preserved LV systolic function in which the left ventricular ejection fraction (LVEF)≥50%.
•Patients with normal renal and hematological functions.
•Alanine amino transferase (ALT ≤ 3 times ULN).

Exclusion Criteria

•Pregnant or lactating females.
•Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 2
•Patients with impaired LV systolic function in which the left ventricular ejection fraction (LVEF)\<50%.
•Patients with significant valvular heart disease, documented coronary artery disease, history of congestive heart failure or cardiomyopathy.
•Alanine amino transferase (ALT \> 3 times ULN).
•Patients already taking statins or other lipid lowering therapy.
•Patients with a known hypersensitivity to any of the used drugs.

Locations (1)

The Department of Clinical Oncology, Tanta University Hospital

Tanta, Egypt

Key Dates

Start Date

September 15, 2020

Primary Completion Date

September 15, 2023

Completion Date

September 15, 2023

Last Updated

February 28, 2024

Enrollment

ACTUAL participants

Conditions

Chemotherapy-induced CardiotoxicityBreast Cancer

Interventions

Rosuvastatin 20mg

DRUG

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer